Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Can Commun Dis Rep ; 47(11): 491-499, 2021 Nov 10.
Article in English | MEDLINE | ID: mdl-34880711

ABSTRACT

BACKGROUND: The International Circumpolar Surveillance (ICS) program conducts surveillance on five invasive bacterial diseases: pneumococcal disease (IPD), group A streptococcus (iGAS), Haemophilus influenzae (Hi), meningococcal disease (IMD) and group B streptococcus (GBS). Invasive bacterial diseases have a higher burden of disease in northern populations than the rest of Canada. METHODS: To describe the epidemiology of invasive bacterial diseases in northern Canada from 1999 to 2018, data for IPD, iGAS, Hi, IMD and GBS were extracted from the ICS program and the Canadian Notifiable Diseases Surveillance System (CNDSS) and analyzed. RESULTS: The annualized incidence rates for IPD, iGAS, Hi, GBS and IMD were 23.3, 10.5, 8.9, 1.9 and 1.1 per 100,000 population, respectively. The incidence of IPD, iGAS and Hi serotype b were 2.8, 3.2 and 8.8 times higher, respectively, in northern Canada than in the rest of Canada. Rates of disease decreased statistically significantly for IPD (ß=-0.02) and increased statistically for iGAS (ß=0.08) and Hi serotype a (ß=0.04) during the study period. In Northern Canada, the annualized incidence rates for IPD, iGAS and Hi were statistically higher for Indigenous residents than for non-Indigenous residents. The highest incidence rates were among the very young and older age groups. CONCLUSION: Invasive bacterial diseases represent a high burden of disease in Canada's northern populations. Indigenous peoples, children and seniors are particularly at risk.

2.
Preprint in English | medRxiv | ID: ppmedrxiv-21258317

ABSTRACT

ObjectivePost COVID-19 condition refers to persisting or recurring symptoms weeks after acute COVID-19 illness which can significantly impact quality of life and health systems. It is important to understand the manifestation and magnitude of this condition. The objective of this living systematic review is to summarize the prevalence of symptoms and sequelae reported by people [≥]4 weeks after COVID-19 diagnosis. DesignSystematic review, meta-analysis and narrative synthesis. Data sourcesEmbase, Medline, PsychInfo, Cochrane Central and select grey literature up to April 14, 2021. MethodsWe adapted a previous search strategy used by the U.K. National Institute for Health and Care Excellence and updated it to search for new literature. Two reviewers screened references independently; one extracted data and assessed risk of bias and certainty of the evidence while another verified them. Prevalence data from laboratory-confirmed populations were meta-analyzed using a random effects model and synthesized separately in the short-term (4-12 weeks) and long-term (>12 weeks) periods after diagnosis. Data from clinically-diagnosed populations were synthesized narratively. ResultsOf the 4444 unique citations, 84 observational studies met our inclusion criteria. Over 100 post COVID-19 symptoms and sequelae were reported. Sixty-one percent (95% CI: 44-76%, low certainty) and 53% (95% CI: 41-65%, low certainty) of laboratory-confirmed individuals reported persistence or presence of one or more symptoms in the short- and long-term periods, respectively. The most prevalent symptoms in both periods included: fatigue, general pain or discomfort, shortness of breath, cognitive impairment and mental health symptoms. ConclusionsA substantial proportion of individuals reported a variety of symptoms [≥]4 weeks after COVID-19 diagnosis. Due to gaps in the research base, and the low certainty of the evidence currently available, further research is needed to determine the true burden of post COVID-19 condition in the general population and in specific subgroups. PROSPERO registration numberCRD42021231476.

3.
Syst Rev ; 8(1): 260, 2019 11 18.
Article in English | MEDLINE | ID: mdl-31735166

ABSTRACT

BACKGROUND: This systematic review was conducted to inform the Canadian Task Force on Preventive Health Care recommendations on screening for thyroid dysfunction (TD). The review sought to answer key questions on the benefits and harms of screening for TD, patients' values and preferences for screening, and the benefits and harms of treating screen-detected TD. METHODS: This review followed Canadian Task Force on Preventive Health Care methods, which include the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. The search strategy used for benefits and harms of screening and treatment was an update to the 2014 review by the US Preventive Services Task Force and searched MEDLINE and the Cochrane Library. MEDLINE, Embase, ProQuest Public Health, and SCOPUS were searched for patients' values and preferences for screening. Outcomes of interest included all-cause mortality, deaths due to cardiovascular diseases, fatal and non-fatal cardiovascular events, atrial fibrillation, fractures, quality of life, cognitive function, and harms due to TD treatment. Two reviewers independently screened abstracts and full texts according to pre-determined inclusion criteria and assessed the risk of bias for each study included. Strength and quality of the evidence was assessed for each outcome. A narrative synthesis was conducted due to heterogeneity of the included studies. RESULTS: No studies were found on screening for TD, treatment of subclinical hyperthyroidism, or patients' values and preferences for screening for TD. Twenty-two studies (from 24 publications) on the treatment of TD in patients with screen-detected subclinical hypothyroidism were included. Results from the included randomized controlled trials suggested no benefit of treatment for subclinical hypothyroidism for the large majority of outcomes. We found very low-quality evidence (from two cohort studies) for a small reduction in all-cause mortality among adults < 65 or 40-70 years who were treated for TD compared to those who were not. CONCLUSIONS: This review found moderate to very low-quality evidence on the benefits and harms of treatment for subclinical hypothyroidism, with most of the evidence showing no benefit of treatment.


Subject(s)
Mass Screening , Thyroid Diseases/diagnosis , Adult , Asymptomatic Diseases/therapy , Humans , Independent Living , Mass Screening/adverse effects , Mass Screening/methods , Thyroid Diseases/therapy
4.
Euro Surveill ; 20(43)2015.
Article in English | MEDLINE | ID: mdl-26804195

ABSTRACT

Respiratory specimens collected from outpatients with influenza-like illness in three Canadian provinces (British Columbia (BC), Alberta and Quebec) participating in a community-based sentinel surveillance network were prospectively screened for enterovirus-D68 (EV-D68) from 1 August to 31 December 2014 and compared to specimens collected from 1 October 2013 to 31 July 2014. Eighteen (1%) of 1,894 specimens were EV-D68-positive: 1/348 (0.3%) collected from October to December 2013 and 11/460 (2.4%) from October to December 2014, an eight-fold increase in detection rates (p=0.01), consistent with epidemic circulation in autumn 2014. The remaining EV-D68 detections were in September 2014 (6/37). Enhanced passive surveillance was also conducted on all inpatient and outpatient EV-D68 cases (n=211) detected at the BC provincial reference laboratory from 28 August to 31 December 2014. Incidence of hospitalisations was 3/100,000 overall and 21, 17, 4 and 1/100,000 among those<5, 5-9, 10-19 and ≥20-years-old with male-to-female ratios>1 among paediatric but not adult cases. Three cases in BC with comorbidity or co-infection died and five exhibited neurological features persisting >9 months. Active surveillance in outpatient and inpatient settings is needed from more areas and additional seasons to better understand EV-D68 epidemiology and potential at-risk groups for severe or unusual manifestations.


Subject(s)
Community-Acquired Infections/diagnosis , Community-Acquired Infections/epidemiology , Disease Outbreaks , Enterovirus D, Human/isolation & purification , Enterovirus Infections/epidemiology , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/epidemiology , Sentinel Surveillance , Adolescent , Adult , Aged , Canada/epidemiology , Child , Child, Preschool , Coinfection/epidemiology , Community-Acquired Infections/virology , Enterovirus D, Human/genetics , Enterovirus Infections/diagnosis , Enterovirus Infections/virology , Female , Hospitalization/statistics & numerical data , Humans , Incidence , Infant , Laboratories, Hospital , Male , Middle Aged , Phylogeny , Prospective Studies , Residence Characteristics , Respiratory Tract Infections/virology , Seasons , Sequence Analysis, DNA , Young Adult
5.
Can Commun Dis Rep ; 40(17): 339-345, 2014 Oct 16.
Article in English | MEDLINE | ID: mdl-29769862

ABSTRACT

Middle East respiratory syndrome - Coronavirus (MERS-CoV) -- is a novel coronavirus that has caused a number of community-acquired cases and health care associated outbreaks in Saudi Arabia and the United Arab Emirates (UAE) as well as sporadic cases in other countries, especially in the Middle East. The evidence to date links MERS-CoV cases with exposure to camels, including camel products or to probable or confirmed human cases of MERS-CoV. It typically presents as an acute respiratory illness and is associated with a 35% mortality rate. Based on available information at this time, the current risk to Canadians for acquiring MERS-CoV infections is considered low. However, the International Health Regulations Committee concerning MERS-CoV has cautioned that the upsurge of cases seen this past spring (2014) may be predictive of an increase in cases related to the Hajj - an annual pilgrimage to Mecca in Saudi Arabia that took place in early October 2014. Although the overall risk is low, the Public Health Agency of Canada and its National Microbiology Laboratory (NML) in close collaboration with provincial and territorial partners, the Canadian Public Health Laboratory Network (CPHLN) and infection prevention and control experts have developed a number of preparedness guidance documents and protocols to address the risk of an imported case of MERS-CoV in Canada.

8.
Rev. méd. domin ; 54(2): 47-9, jul.-sept. 1993.
Article in Spanish | LILACS | ID: lil-132101

ABSTRACT

Con el propósito de conocer la incidencia de ameba histolítica y giardia lamblia en niños con diarrea crónica, fueron estudiados 50 pacientes con esta patología en el área de rehidratación oral del hospital infantil Dr. Robert Reid Cabral, en Santo Domingo, República Dominicana. Resultó que 56 por ciento (28 casos) estaban afectados por estos parásitos. El 50 por ciento (14 casos) eran menores de 6 meses de edad, seguidos por los de 7 a 12 meses con 17.8 por ciento (9 casos). El tipo de diarrea crónica más frecuente fue la recidivante con 64 por ciento (32 pacientes). Se detrnimó que el 75 por ciento (21 casos) de las madres de los niños afectados por la ameba y giardia no se lavaban las manos antes de preparar los alimentos


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Giardia lamblia/isolation & purification , Diarrhea, Infantile/etiology , Amoeba/isolation & purification , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...